Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.
Family Medicine/General Practice October 16th 2024
Medical Xpress
The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.
Oncology, Medical October 8th 2024
Cancer Therapy Advisor
AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.
Oncology News Central (ONC)
Striking the balance between confidence and humility is crucial for new oncology attendings, especially when managing rare cases.
Hematology/Oncology October 8th 2024
The New England Journal of Medicine
In a population-based trial, MRI-targeted biopsy significantly reduced the detection of clinically insignificant prostate cancer compared to systematic biopsy, without increasing the risk of advanced cancer detection. These findings support the use of MRI-targeted biopsy as a more efficient and safer screening method.
MDLinx
Researchers identified the post-fast refeeding period as a distinct state with greater potential for tumor proliferation compared to the fasted or continuously fed state.
Endocrinology, Diabetes, Metabolism September 25th 2024